Last $93.89 USD
Change Today -0.01 / -0.01%
Volume 891.1K
NVS On Other Exchanges
New York
SIX Swiss Ex
As of 3:26 PM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-adr (NVS) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/17/14 - $95.50
52 Week Low
10/10/13 - $72.77
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NOVARTIS AG-ADR (NVS)

novartis ag-adr (NVS) Details

Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism. The company’s Alcon division provides various eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates, primarily antibiotics; protein or biotechnology-based products; cytotoxic products for the hospital market; and biotech manufacturing services to other companies. The company’s Vaccines and Diagnostics division provides preventive human vaccines. Its Consumer Health division offers over-the-counter medicines comprising readily available consumer medicines; and Animal Health, which provides veterinary products for farm and companion animals. The company distributes its OTC products through various channels, such as food, drug, and mass retail outlets, as well as pharmacies; and Animal Health products directly and through wholesalers of veterinary products. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

135,000 Employees
Last Reported Date: 07/17/14
Founded in 1895

novartis ag-adr (NVS) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: SFr.3.1M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: SFr.747.1K
President of Institutes for Biomedical Resear...
Total Annual Compensation: $1.9M
Division Head of Novartis Pharmaceuticals and...
Total Annual Compensation: $2.0M
Division Head of Animal Health and Member of ...
Total Annual Compensation: SFr.1.4M
Compensation as of Fiscal Year 2013.

novartis ag-adr (NVS) Key Developments

Novartis and University of Pennsylvania Establish New Centre for Car-Based Cancer Therapeutics

Novartis (Switzerland) and the University of Pennsylvania have unveiled plans to establish a Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus. The 30,000 square foot research facility focused on the development of chimeric antigen receptor (CAR) therapies. The CACT will be funded with a USD 20 million investment from Novartis, and is anticipated to employ 100 high specialized professionals including scientists and clinicians from Penn and Novartis to discover, develop and manufacture these personal therapies. The facility is expected to be completed in 2016, and will include additional space to technologically advanced rooms where patient's immune cells will be processed, as well as new functions for the space including vaccine development, assay development, and correlative studies of biospecimens to assess patients' response to treatment.

Novartis Presents Data from the Phase III LANTERN Trial

Novartis presented data from the Phase III LANTERN trial, at the European Respiratory Society (ERS) International Congress, showing the superiority of its once-daily Ultibro Breezhaler (indacaterol + glycopyrronium bromide) over twice-daily Seretide Accuhaler (salmeterol + fluticasone; SFC) in reducing exacerbations and improving lung function in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). Specifically, the new data presented by the company demonstrate that Ultibro Breezhaler was associated with a significant reduction of 31% in the rate of moderate-to-severe exacerbations in comparison with SFC as well as showed that the drug significantly increased lung function compared with SFC following 26 weeks of treatment.

Novartis Presents Results of its PARADIGM-HF Trial

Novartis (NVS) has presented results of its PARADIGM-HF trial, demonstrating its investigational heart failure medicine, LCZ696, was superior to ACE-inhibitor enalapril on key endpoints in heart failure study. LCZ696 reduced the risk of death from cardiovascular causes by 20%, reduced heart failure hospitalizations by 21%, and reduced the risk of all-cause mortality by 16%. Overall there was a 20% risk reduction on the primary endpoint, a composite measure of CV death or heart failure hospitalization. Results were presented at the European Society of Cardiology congress and published in the New England Journal of Medicine. Novartis plans to file the New Drug Application for review with the US FDA by the end of 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $93.89 USD -0.01

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $105.30 USD -0.66
Merck & Co Inc $60.61 USD +0.12
Pfizer Inc $30.11 USD -0.29
Roche Holding AG SFr.283.20 CHF 0.00
Procter & Gamble Co/The $84.75 USD +0.28
View Industry Companies

Industry Analysis


Industry Average

Valuation NVS Industry Range
Price/Earnings 25.2x
Price/Sales 3.9x
Price/Book 3.2x
Price/Cash Flow 26.0x
TEV/Sales 3.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at